Merck's eye disease drug meets main goal in trial
- Posted on September 24, 2026
- By Bing News
- 0 Views
- 1 min read
In brief
Generating AI summary…
Merck's eye disease drug meets main goal in trial
Sept 24 (Reuters) - Merck said on Thursday its drug met the main goal in a mid- to late-stage trial testing it in adult patients with a type of disease that affects blood vessels at the back of the eye. The company said its drug, remigromig, demonstrated non-inferiority when compared with control drug ranibizumab in patients with diabetic macular edema. It is a serious eye condition that causes
